Analyst consensus rating
Fulcrum Therapeutics Analyst Rating: none
Direct answer
Fulcrum Therapeutics's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $3.67.
Forecast evidence checked November 12, 2026.
Get free Fulcrum Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.74
- Average price target
- $3.67
- High price target
- $4.00
- Low price target
- $3.00
- Low target gap
- -19.8%
- Target upside
- -2%
- High target gap
- +7%
- Target range width
- 26.7%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Fulcrum Therapeutics?
Fulcrum Therapeutics has a verified none consensus. The same dataset has an average price target of $3.67.
How far are Fulcrum Therapeutics's low and high targets from the recorded price?
The low target implies -19.8%, while the high target implies +7%.
How many analysts are included in Fulcrum Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Fulcrum Therapeutics's target upside or downside calculated?
The average target of $3.67 is divided by the recorded price of $3.74, then one is subtracted to produce -2%. This does not guarantee a future return.
When was Fulcrum Therapeutics's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.